Movement-evoked hyperalgesia induced by lipopolysaccharides is not suppressed by glucocorticoids

Pain

Volumn 136, Issue 1-2, 2008, Pages 75-84

  Kovács, Katalin J ^a   Papic, Jonathan C ^a   Larson, Alice A ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

Author keywords

Corticosterone; Endotoxemia; Glucocorticoid; Grip force; Mouse; Myalgia

Indexed keywords

DEXAMETHASONE; GLUCOCORTICOID; GLUCOCORTICOID ANTAGONIST; LIPOPOLYSACCHARIDE; MIFEPRISTONE;

ADRENALECTOMY; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROL GROUP; CONTROLLED STUDY; DRUG ACTIVITY; DRUG FATALITY; FEMALE; HYPERALGESIA; INCIDENCE; LETHALITY; MORTALITY; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ADRENALECTOMY; ANIMALS; FEMALE; GLUCOCORTICOIDS; HYPERALGESIA; INFLAMMATION MEDIATORS; LIPOPOLYSACCHARIDES; MICE; MOVEMENT;

EID: 41849118804     PISSN: 03043959     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pain.2007.06.017     Document Type: Article

References (80)

1. Aosasa S., Ono S., Mochizuki H., Tsujimoto H., Osada S., Takayama E., et al. Activation of monocytes and endothelial cells depends on the severity of surgical stress. World J Surg 24 (2000) 10-16
2. Barbara G., Vallance B.A., and Collins S.M. Persistent intestinal neuromuscular dysfunction after acute nematode infection in mice. Gastroenterology 113 (1997) 1224-1232
3. Barton A., Pal B., Whorwell P.J., and Marshal D. Increased prevalence of sicca complex and fibromyalgia in patients with irritable bowel syndrome. Am J Gastroenterol 94 (1999) 1898-1901
4. Beasley D., Schwartz J.H., and Brenner B.M. Interleukin-a induces prolonged l-arginine-dependent cyclic guanosine monophosphate and nitrite production in rat vascular smooth muscle cell. J Clin Invest 87 (1991) 602-608
5. Berki T., Pálinkás L., Boldizsár F., and Németh P. Glucocorticoid (GC) sensitivity and GC receptor expression differ in thymocyte subpopulations. Int Immunol 14 (2002) 463-469
6. Bertini R., Bianchi M., and Ghezzi P. Adrenalectomy sensitizes mice to the lethal effects of interleukin 1 and tumor necrosis factor. J Exp Med 167 (1988) 1708-1712
7. Beutler B., Milsark I.W., and Cerami A.C. Passive immunization against cachectin/tumor necrosis factor protects mice from lethal effect of endotoxin. Science 229 (1985) 869-871
8. Buttenschoen K., Berger D., Strecker W., Buttenschoen D.C., Stenzel K., Pieper T., et al. Association of endotoxemia and production of antibodies against endotoxins after multiple injuries. J Trauma 48 (2000) 918-923
9. Cahill C.M., Dray A., and Coderre T.J. Priming enhances endotoxin-induced thermal hyperalgesia and mechanical allodynia in rats. Brain Res 808 (1998) 13-22
10. Caradonna L., Amati L., Magrone T., Pellegrino N.M., Jitillo E., and Caccavo D. Enteric bacteri, lipopolysaccharides and related cytokines in inflammatory bowel disease: biological and clinical significance. J Endotoxin Res 6 (2000) 205-214
11. Davies E., and MacKenzie S.M. Extra-adrenal production of corticosteroids. Clin Exp Pharmacol Physiol 30 (2003) 437-445
12. Decker K. Biologically active products of stimulated liver macrophages (kupffer cells). Eur J Biochem 192 (1990) 245-261
13. Evans G.F., and Zuckerman S.H. Glucocorticoid-dependent and -independent mechanisms involved in lipopolysaccharide tolerance. Eur J Immunol 21 (1991) 1973-1979
14. Ferreira S.H., Lorenzetti B.B., Bristow A.F., and Pooles S. Interleukin-1 beta as a potent hyperalgesic agent antagonized by a tripeptide analogue. Nature 334 (1988) 698-700
15. Fox E.S., Thomas P., and Broitman S.A. Clearance of gut-derived endotoxin by the liver. Release and modification of 3H, 14C-lipopolysaccharide by isolated rat Kupffer cells. Gastroenterology 96 (1989) 456-461
16. Gardiner K.R., Halliday M.I., Barclay G.R., Milne L., Brown D., Stephens S., et al. Significance of systemic endotoxaemia in inflammatory bowel disease. Gut 36 (1995) 897-901
17. Geller P., Merrill E.R., and Jawetz E. Effects of cortisone and antibiotics on lethal action of endotoxin in mice. PSEBM 86 (1954) 716-719
18. Hochstein H.D., Fitzgerald E.A., McMahon F.G., and Vargas R. Properties of US standard endotoxin (EC-5) in human male volunteers. J Endotoxin Res 1 (1994) 52-56
19. Hotta T., Yoshida N., Yoshikawa T., Sugino S., and Kondo M. Lipopolysaccharide-induced colitis in rabbits. Res Exp Med 186 (1986) 61-69
20. Ignatowski T.A., Covery W.C., Knight P.R., Severin C.M., Nickola T.J., and Spengler R.N. Brain-derived TNF-α mediates neuropathic pain. Brain Res 841 (1999) 70-77
21. Jasmin L., Jani G., Manz H.J., and Rabkin S.D. Activation of CNS circuits producing a neurogenic cystitis: evidence for centrally induced peripheral inflammation. J Neurosci 18 (1998) 10016-10129
22. Jasper M.S., and Engeland W.C. Synchronous ultradian rhythms in adrenocortical secretion detected by microdialysis in awake rats. Am J Physiol 261 (1991) R1257-R1268
23. Jiang J.X., Tian K.L., Chen H.S., Zhu P.F., and Wang Z.G. Plasma cytokines and endotoxin levels in patients with severe injury and their relationship with organ damage. Injury 28 (1997) 509-513
24. Johnston I.N., and Westbrook R.F. Acute and conditioned sickness reduces morphine analgesia. Behavior Brain Res 142 (2003) 89-97
25. Jungi T.W., Miserez R., Brcic M., and Pfister H. Change in sensitivity to lipopolysaccharide during the differentiation of human monocytes to macrophages in vitro. Experientia 50 (1994) 110-114
26. Kanaan S.A., Saade N.E., Haddad J.J., Abdelnoor A.M., Atweh S.F., Jabbur S.J., et al. Endotoxin-induced local inflammation and hyperalgesia in rats and mice: a new model for inflammatory pain. Pain 66 (1996) 373-379
27. Kehl L.J., Trempe T.M., and Hargreaves K.M. A new animal model for assessing mechanisms and management of muscle hyperalgesia. Pain 85 (2000) 333-343
28. Kehl L.J., Hamamoto D.T., Wacnik P.W., Croft D.L., Norsted B.D., Wilcox G.L., et al. A cannabinoid agonist differentially attenuates deep tissue hyperalgesia in animal models of cancer and inflammatory muscle pain. Pain 103 (2003) 175-186
29. Kehl L.J., Kovács K.J., and Larson A.A. Tolerance develops to the effect of lipopolysaccharides on movement-evoked hyperalgesia when administered chronically by a systemic but not an intrathecal route. Pain 111 (2004) 104-115
30. Knowles R.G., Salter M., Brooks S.L., and Moncada S. Anti-inflammatory glucocorticoids inhibit the induction by endotoxin of nitric oxide synthase in the lung, liver and aorta of the rat. Biochem Biophys Res Commun 172 (1990) 1042-1048
31. Lazar G., Sekiya S., and Agarwal M.K. Influence of steroid structure in relation to liver metabolism during endotoxin lethality in mice. Exp Cell Biol 45 (1977) 176-183
32. Lewin G.R., and Mendell L.M. Nerve growth factor and nociception. Trends Neurosci 16 (1993) 353-359
33. Liehr H. Endotoxins and the pathogenesis of gastrointestinal diseases. MMW-Munch Med Wochenschr 123 (1981) 53-56
34. Linde A., Andersson B., Svenson S.B., Ahrne H., Carlsson M., Forsberg P., et al. Serum levels of lymphokines and soluble cellular receptors in primary Epstein-Barr virus infection and in patients with chronic fatigue syndrome. J Infect Dis 165 (1992) 994-1000
35. Lynn M., Rossignol D.P., Wheeler J.L., Kao R.J., Perdomo C.A., Noveck R., et al. blocking of responses to endotoxin by E5564 in healthy volunteers with experimental endotoxemia. J Infect Dis 187 (2003) 631-639
36. Maier S.F., Wiertelak E.P., Martin D., and Watkins L.R. Interleukin-1 mediates the behavioral hyperalgesia produced by lithium chloride and endotoxin. Brain Res 623 (1993) 321-324
37. McGregor N.R., Dunstan R.H., Zerbes M., Butt H.L., Roberts T.K., and Klineberg I.J. Preliminary determination of the association between symptom expression and urinary metabolites in subjects with chronic fatigue syndrome. Biochem Mol Med 58 (1996) 733-739
38. McKay L.I., and Cidlowski J.A. Molecular control of immune/inflammatory responses: interactions between nuclear factor-kappa B and steroid receptor-signaling pathways. Endocr Rev 20 (1999) 435-459
39. Meller S.T., Dykstra C., Grzbycki D., Murphy S., and Gebhart G.F. The possible role of glia in nociceptive processing and hyperalgesia in the spinal cord of the rat. Neuropharmacology 33 (1994) 1471-1478
40. Monajemi H., Meenan J., Lamping R., Obradov D.O., Radema S.A., Trown P.W., et al. Inflammatory bowel disease is associated with increased mucosal levels of bactericidal/permeability-increasing protein. Gastroenterology 110 (1996) 733-739
41. Nakao A., Taki S., Yasui M., Kimura Y., Nonami T., Harada A., et al. The fate of intravenously injected endotoxin in normal rats and in rats with liver failure. Hepatology 19 (1994) 1251-1256
42. Nathan C.F. Secretory products of macrophages. J Clin Invest 79 (1987) 319-326
43. Nava F., Calapai G., De Sarro A., and Caputi A.P. Interleukin-1 receptor antagonist does not reverse lipopolysaccharide-induced inhibition of water intake in rat. Eur J Pharmacol 309 (1996) 223-227
44. Nava F., Calapai G., Facciola G., Cuzzocrea S., Marciano M.C., DeSarro A., et al. Effects of interleukin-10 on water intake, locomotory activity, and rectal temperature in rat treated with endotoxin. Int J Immunopharmacol 19 (1997) 31-38
45. Nava F., Calapai G., Facciola G., Cuzzocrea S., Giuliani G., DeSarro A., et al. Melatonin effects on inhibition of thirst and fever induced by lipopolysaccharide in rat. Eur J Pharmacol 331 (1997) 267-274
46. Nava F., and Caputi A.P. Central effects of cromoglycate sodium salt in rats treated with lipopolysaccharide. Eur J Pharmacol 367 (1999) 351-359
47. Nava F., and Carta G. Repeated lipopolysaccharide administration produces tolerance to anorexia and fever but not to inhibition of thirst in rat. Int J Immunopharmacol 22 (2000) 943-953
48. Nazar P.S., and Smishchuk I.O. The mucosal status of the large intestine in the irritable bowel syndrome and in chronic noninfectious nonspecific colitis. Lik Sprava 7 (1998) 111-114
49. Nevins M.E., Nash S.A., and Beardsley P.M. Quantitative grip strength assessment as a means of evaluating muscle relaxation in mice. Psychopharmacology 110 (1993) 92-96
50. O'Neill L.A., and Lewis G.P. Interleukin-1 potentiates bradykinin and TNF-alpha-induced PGE2 release. Eur J Pharmacol 166 (1989) 131-137
51. Petty B.G., Cornblath D.R., Adornato B.T., Chaudhry V., Flexner C., Wachsman M., et al. The effect of systemically administered recombinant human nerve growth factor in healthy human subjects. Ann Neurol 36 (1994) 244-246
52. Philibert D., and Teutsch G. RU 486 development. Science 247 (1990) 622
53. Quan N., Stern E.L., Whiteside M.B., and Herkenham M. Induction of pro-inflammatory cytokine mRNAs in the brain after peripheral injection of subseptic doses of lipopolysaccharide in the rat. J Neuroimmunol 93 (1999) 72-80
54. Radomski M.W., Palmer R.M., and Moncada S. Glucocorticoids inhibit the expression of an inducible, but not the constitutive, nitric oxide synthase in vascular endothelial cells. Proc Natl Acad Sci USA 87 (1990) 10043-10047
55. Raetz C.R. Biochemistry of endotoxins. Annu Rev Biochem 59 (1990) 129-170
56. Raghavendra V., Agrewala J.N., and Kulkarni S.K. Melatonin reversal of lipopolysaccharides-induced thermal and behavioral hyperalgesia in mice. Eur J Pharmacol 395 (2000) 15-21
57. Riddington D.W., Venkatesh B., Boivin C.M., Bonser R.S., Elliott T.S., Marshall T., et al. Intestinal permeability, gastric intramucosal pH, and systemic endotoxemia in patients undergoing cardiopulmonary bypass. JAMA 275 (1996) 1007-1012
58. Rietschel E., Kirikae T., Schade U., Mamat U., Schimidt G., Loppnow H., et al. Bacterial endotoxin: molecular relationships of structure to activity and function. FASEB J 8 (1994) 217-225
59. Safieh-Garabedian B., Poole S., Allchorne A., Winter J., and Woolf C.J. Contribution of interleukin-1β to the inflammation-induced increase in nerve growth factor levels and inflammatory hyperalgesia. Br J Pharmacol 115 (1995) 1265-1275
60. Safieh-Garabedian B., Poole S., Allchorne A., Kanaan S., Saade N., and Woolf C.J. Zinc reduces the hyperalgesia and upregulation of NGF and IL-1β produced by peripheral inflammation in the rat. Neuropharmacology 35 (1996) 599-603
61. Safieh-Garabedian B., Kanaan S.A., Haddad J.J., Jaoude P.A., Jabbur S.J., and Saade N.E. Involvement of interleukin-1 β, nerve growth factor and prostaglandin E2 in endotoxin-induced localized inflammatory hyperalgesia. Br J Pharmacol 121 (1997) 1619-1626
62. Sergio G., Esposito P., Ferraro L., Insidioso M., Pane P., and Zagaria M.P. The limulus test of the cerebrospinal fluid in the diagnosis of disc herniation and its possible correlation with the auto-immune pathogenesis of root pain. Ital J Orthop Traumatol 8 (1982) 199-204
63. Shapira L., Champagne C., Van Dyke T.E., and Amar S. Strain-dependent activation of monocytes and inflammatory macrophages by lipopolysaccharide of Porphyromonas gingivalis. Infect Immun 66 (1998) 2736-2742
64. Sivri A., Cindas A., Dincer F., and Sivri B. Bowel dysfunction and irritable bowel syndrome in fibromyalgia patients. Clin Rheumatol 15 (1996) 283-286
65. Sperber A.D., Atzmon Y., Neumann L., Weisberg I., Shalit Y., Abu-Shakrah M., et al. Fibromyalgia in the irritable bowel syndrome: studies of prevalence and clinical implications. Am J Gastroenterol 94 (1999) 3541-3546
66. Tadano T., Namioka M., Nakagawasai O., Tan-No K., Matsushima K., Endo Y., et al. Induction of nociceptive responses by intrathecal injection of interleukin-1 in mice. Life Sci 65 (1999) 255-261
67. Takemura T., Makino S., Takao T., Asaba K., Suemaru S., and Hashimoto K. Hypothalamic-pituitary-adrenocortical responses to single vs. repeated endotoxin lipopolysaccharide administration in the rat. Brain Res 767 (1997) 181-191
68. Thrivikraman K.V., and Plotsky P.M. Absence of glucocorticoid negative feedback to moderate hemorrhage in conscious rats. Am J Physiol 264 (1993) E497-E503
69. Tobin R.W., and Kimmey M.B. Painful diseases of the gastrointestinal tract. In: Loeser J.D. (Ed). Bonica's management of pain. 3rd ed. (2001), Lippincott Williams & Wilkins, Philadelphia 1269-1292
70. Tracey K.J., Beutler B., Lowry S.F., Merryweather J., Wolpe S., Milsark I.W., et al. Shock and tissue injury induced by recombinant human cachectin. Science 234 (1986) 470-474
71. Van Leeuwen P.A., Boermeester M.A., Houdijk A.P., Ferwerda C.C., Cuesta M.A., Meyer S., et al. Clinical significance of translocation. Gut 35 (1994) S28-S34
72. Wacnik P.W., Kehl L.J., Trempe T.M., Ramnaraine M.L., Beitz A.J., and Wilcox G.L. Tumor implantation in mouse humerus evokes movement-related hyperalgesia exceeding that evoked by intramuscular carrageenan. Pain 101 (2003) 175-186
73. Walker K., Dray A., and Perkins M. Hyperalgesia in rats following intracerebroventricular administration of endotoxin: effect of bradykinin B1 and B2 receptor antagonist treatment. Pain 65 (1996) 211-219
74. Watkins L.R., Wiertelak E.P., Furness L.W., and Maier S.F. Illness-induced hyperalgesia is mediated by spinal neuropeptides and excitatory amino acids. Brain Res 664 (1994) 17-24
75. Watkins L.R., Wiertelak E.P., Goehler L.E., Mooney-Heiberger K., Martinez J., Furness L., et al. Neurocircuitry of illness-induced hyperalgesia. Brain Res 639 (1994) 283-299
76. Watkins L.R., Wiertelak E.P., Goehler L.E., Smith K.P., Martin D., and Maier S.F. Characterization of cytokine induced hyperalgesia. Brain Res 654 (1994) 15-26
77. Wiertelak E.P., Furness L., Watkins L.R., and Maier S.F. Illness-induced hyperalgesia is mediated by a spinal NMDA-nitric oxide cascade. Brain Res 664 (1994) 9-16
78. Wiertelak E.P., Smith K.P., Furness L., Mooney-Heiberger K., Mayr T., Maier S.F., et al. Acute and conditioned hyperalgesic responses to illness. Pain 56 (1994) 227-234
79. Yassin M.M., Dsa A.B., Parks T.G., Soong C.V., Halliday M.I., Mccaigue M.D., et al. Lower limb ischemia-reperfusion injury causes endotoxemia and endogenous antiendotoxin antibody consumption but not bacterial translocation. Br J Surg 85 (1998) 785-789
80. Zweigner J., Gramm H.-J., Singer O.C., Wegscheider K., and Schumann R.R. High concentrations of lipopolysaccharide-binding protein in serum of patients with sever sepsis or septic shock inhibit the lipopolysaccharide response in human monocytes. Blood 98 (2001) 3800-3808